The Hospital for Sick Children and St Michael’s Hospital to Evaluate Innovotech’s bioFILM PATM Test

EDMONTON, ALBERTA–(EMWNews – July 29, 2008) – Innovotech Inc. (TSX VENTURE:IOT) is pleased to announce a three year study by the Hospital for Sick Children and St. Michael’s Hospital to evaluate bioFILM PA^TM, Innovotech’s novel biofilm antimicrobial susceptibility test, in the selection of antibiotics to treat lung infections in cystic fibrosis patients.

“bioFILM PA^TM is a Health Canada registered product, and is therefore available for use by physicians and diagnostic laboratories in the treatment of a host of biofilm respiratory infections” says Dr Bhavin Rawal, Product Manager, Innovotech. “Our early results in cystic fibrosis show promise, so it is appropriate to continue the evaluation of bioFILM PA^TM, particularly with the Hospital for Sick Children and St Michael’s Hospital, given their international reputation in this field.”

Dr Valerie Waters, Infectious disease physician, Dr Yvonne Yau, Clinical microbiologist, from the Hospital for Sick Children, and Dr Elizabeth Tullis, Head, Division of Respirology, St Michael’s Hospital, will evaluate bioFILM PA^TM as a diagnostic tool to improve the treatment of lung disease in cystic fibrosis patients.

The National Research Council’s Industrial Research Assistance Program (IRAP) has provided funding for the study.

About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry. No diagnostics or antibiotics are currently approved for use in infections involving biofilms.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.